Sivik Global Healthcare LLC Has $6.83 Million Stake in Boston Scientific Corporation $BSX

Sivik Global Healthcare LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 12.5% during the third quarter, Holdings Channel reports. The firm owned 70,000 shares of the medical equipment provider’s stock after selling 10,000 shares during the quarter. Boston Scientific makes up approximately 2.0% of Sivik Global Healthcare LLC’s portfolio, making the stock its 6th largest holding. Sivik Global Healthcare LLC’s holdings in Boston Scientific were worth $6,834,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth approximately $26,000. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Steph & Co. acquired a new position in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. bought a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Finally, Kilter Group LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $97.70 on Wednesday. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company’s 50 day moving average price is $97.72 and its two-hundred day moving average price is $100.85. The firm has a market cap of $144.84 billion, a PE ratio of 52.25, a PEG ratio of 1.69 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BSX shares. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Morgan Stanley increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, Royal Bank Of Canada upped their target price on Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $124.95.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.